New CEO Bryant offers quick view of Quidel

Oct. 1, 2009

Douglas C. Bryant


President/CEO, Quidel Corp.,
March 2009 to present

Luminex Corp., Executive VP/COO,
2007 to 2009

Abbott Laboratories,
various worldwide commercial operations positions,

1983 to 2007


BA in Economics,
 University of California-Davis.


Involved in various civic-minded

and professional organizations.


A quarter century.
Quidel launched its first product, a dipstick-based pregnancy test, 25
years ago. Over the past decade, we have introduced a number of
products, including our first rapid influenza test and a next-generation
product, QuickVue Influenza A+B test, the QuickVue iFOB (immunochemical
fecal occult blood) test and the QuickVue RSV test. The company's
current areas of focus are women's health, infectious diseases,
oncology, autoimmune diseases, and osteoporosis.

Looking forward. We are planning a few new product launches by 2010, including a
second-generation fecal occult blood test set to launch by the end of
2009, and a combination influenza/respiratory syncytial virus (RSV)
test. The latter test is expected to enter clinical testing during this
year's flu and RSV season. In addition, a number of physician office
laboratories have asked us for more products, such as a mononucleosis
test, which we have planned for 2010. The company also expects to
innovate in the area of molecular diagnostics, particularly for the
detection of infectious diseases.

Rapid results. In the beginning of 2009, the flu season was mild, and distributors were
already well-stocked, whereas, in the second quarter, there was an
unusually high demand for influenza tests. We have sought to even things
out by shifting to just-in-time manufacturing. The just-in-time model is
also expected to help with similar inventory matters for our strep and
pregnancy tests. Further, the company instituted a program two years ago
to develop correlation test panels that can help acute-care labs
correlate and perhaps substitute their tests with our rapid flu tests if

Test prep. Because the results of a point-of-care test can have a significant
impact on the type and level of patient treatment, we have taken a
number of initiatives to educate and inform the healthcare community
regarding methodologies and procedures for use of our tests. In a recent
webinar, we demonstrated detailed methods for achieving optimal results
with the QuickVue Influenza A+B Test. We offer training videos and
websites to distribute helpful information to healthcare workers. We
also have several websites dedicated to informing the patient about
specific illnesses, such as colorectal cancer and RSV, along with
information about the tests their physicians may be ordering.

Knowledge is power. Our mission is to enhance the health and well-being of people around the
globe, so the core focus of our charitable giving is on health
education. We have partnered with organizations that supply individuals
with information to help them live healthier lives and/or mitigate the
effects of disease. Most recently, we worked with the UC-SD Moores
Cancer Center in San Diego, where the company has funded informational
pamphlets, nutrition classes, and educational programs for cancer
patients. We also have a matching-gifts program and a
volunteer-incentive program, through which the company makes a donation
to qualifying non-profits when employees donate 20 hours or more of
their time in service to that organization. Some of our employees have
volunteered with Doctors without Borders, Voices for Children, and the
Disepio Institute for Rural Health and Wellness at St. Francis
University in Pennsylvania.